Key Points
-
Lower urinary tract (LUT) symptoms are common in patients with multiple sclerosis; the exact symptoms vary in type and severity, and can evolve with progression of the disease
-
The management of LUT dysfunction in these patients requires a consensual approach, with cooperation between different medical professionals, and should take into consideration possible progression of the disease
-
Intermittent self-catheterization is essential for the management of patients with voiding symptoms, but might also have a role in management of those with storage symptoms
-
Intradetrusor botulinum toxin A injections are a highly effective and minimally invasive treatment of storage dysfunctions
-
Surgical options include augmentation cystoplasty, cutaneous continent diversion and ileal conduit surgery, and should be performed only after careful selection of patients
-
Multiple sclerosis has a progressive course and, therefore, patients with multiple sclerosis who also have LUT symptoms require regular long-term follow-up monitoring
Abstract
Lower urinary tract (LUT) dysfunction is common in patients with multiple sclerosis and is a major negative influence on the quality of life of these patients. The most commonly reported symptoms are those of the storage phase, of which detrusor overactivity is the most frequently reported urodynamic abnormality. The clinical evaluation of patients' LUT symptoms should include a bladder diary, uroflowmetry followed by measurement of post-void residual urine volume, urinalysis, ultrasonography, assessment of renal function, quality-of-life assessments and sometimes urodynamic investigations and/or cystoscopy. The management of these patients requires a multidisciplinary approach. Intermittent self-catheterization is the preferred option for management of incomplete bladder emptying and urinary retention. Antimuscarinics are the first-line treatment for patients with storage symptoms. If antimuscarinics are ineffective, or poorly tolerated, a range of other approaches, such as intradetrusor botulinum toxin A injections, tibial nerve stimulation and sacral neuromodulation are available, with varying levels of evidence in patients with multiple sclerosis. Surgical procedures should be performed only after careful selection of patients. Stress urinary incontinence owing to sphincter deficiency remains a therapeutic challenge, and is only managed surgically if conservative measures have failed. Multiple sclerosis has a progressive course, therefore, patients' LUT symptoms require regular, long-term follow-up monitoring.
Similar content being viewed by others
References
Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the world. [online], (2013).
Confavreux, C., Aimard, G. & Devic, M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain J. Neurol. 103, 281–300 (1980).
Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain J. Neurol. 128, 2705–2712 (2005).
Furby, J. et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult. Scler. 14, 1068–1075 (2008).
Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).
Derfuss, T., Bergvall, N. K., Sfikas, N. & Tomic, D. L. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr. Med. Res. Opin. 31, 1687–1691 (2015).
Nortvedt, M. W. et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult. Scler. 13, 106–112 (2007).
Betts, C. D., D'Mellow, M. T. & Fowler, C. J. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 56, 245–250 (1993).
Fowler, C. J. et al. A UK consensus on the management of the bladder in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80, 470–477 (2009).
Khan, F., Pallant, J. F., Shea, T. L. & Whishaw, M. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil. Rehabil. 31, 1567–1576 (2009).
Hemmett, L., Holmes, J., Barnes, M. & Russell, N. What drives quality of life in multiple sclerosis? QJM 97, 671–676 (2004).
Marrie, R. A., Cutter, G., Tyry, T., Vollmer, T. & Campagnolo, D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 68, 1971–1978 (2007).
Mayo, M. E. & Chetner, M. P. Lower urinary tract dysfunction in multiple sclerosis. Urology 39, 67–70 (1992).
Giannantoni, A. et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol. Urodyn. 17, 89–98 (1998).
Koldewijn, E. L., Hommes, O. R., Lemmens, W. A. J. G., Debruyne, F. M. J. & Van Kerrebroeck, P. E. V. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J. Urol. 154, 169–173 (1995).
Gallien, P. et al. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch. Phys. Med. Rehabil. 79, 255–257 (1998).
Kasabian, N. G., Krause, I., Brown, W. E., Khan, Z. & Nagler, H. M. Fate of the upper urinary tract in multiple sclerosis. Neurourol. Urodyn. 14, 81–85 (1995).
Amarenco, G., Kerdraon, J. & Denys, P. Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases. Rev. Neurol. (Paris) 151, 722–730 (in French) (1995).
Murphy, A. M., Bethoux, F., Stough, D. & Goldman, H. B. Prevalence of stress urinary incontinence in women with multiple sclerosis. Int. Neurourol. J. 16, 86–90 (2012).
de Seze, M. et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult. Scler. 13, 915–928 (2007).
Panicker, J. & Haslam, C. Lower urinary tract dysfunction in MS: management in the community. Br. J. Community Nurs. 14, 474–480 (2009).
Mahajan, S. T., Patel, P. B. & Marrie, R. A. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J. Urol. 183, 1432–1437 (2010).
Araki, I., Matsui, M., Ozawa, K., Takeda, M. & Kuno, S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J. Urol. 169, 1384–1387 (2003).
Porru, D. et al. Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters? Spinal Cord 35, 33–36 (1997).
Ciancio, S. J., Mutchnik, S. E., Rivera, V.M. & Boone, T. B. Urodynamic pattern changes in multiple sclerosis. Urology 57, 239–245 (2001).
Giannantoni, A. et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch. Phys. Med. Rehabil. 80, 437–441 (1999).
De Ridder, D. et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J. Urol. 159, 1881–1884 (1998).
Desgrippes, A., Meria, P., Cortesse, A., Cochand-Priollet, B. & Cariou, G. Epidermoid carcinoma of the bladder [French]. Prog. Urol. 8, 321–329 (1998).
Hennessey, A., Robertson, N. P., Swingler, R. & Compston, D. A. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J. Neurol. 246, 1027–1032 (1999).
Perrigot, M., Richard, F., Veaux-Renault, V., Chatelain, C. & Küss, R. Bladder sphincter disorders in multiple sclerosis: symptomatology and evolution. 100 cases [French]. Sem. Hôp. 58, 2543–2546 (1982).
Lawrenson, R., Wyndaele, J. J., Vlachonikolis, I., Farmer, C. & Glickman, S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 20, 138–143 (2001).
Castel-Lacanal, E. et al. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurourol. Urodyn. 34, 32–36 (2015).
Abrams, P., Cardozo, L., Khoury, S. & Wein, A. (eds) Incontinence 5th edn (ICUD press, 2013).
Bonniaud, V. et al. Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen. Qual. Life Res. 14, 425–431 (2005).
Blok, B. et al. Guidelines on neuro-urology. European Association of Urology [online], (2015).
Fowlis, G. A., Waters, J. & Williams, G. The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J. R. Soc. Med. 87, 681–682 (1994).
Khasriya, R. et al. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J. Urol. 183, 1843–1847 (2010).
Schwartz, D. S. & Barone, J. E. Correlation of urinalysis and dipstick results with catheter-associated urinary tract infections in surgical ICU patients. Intensive Care Med. 32, 1797–1801 (2006).
Mimoz, O., Bouchet, E., Edouard, A., Costa, Y. & Samii, K. Limited usefulness of urinary dipsticks to screen out catheter-associated bacteriuria in ICU patients. Anaesth. Intensive Care 23, 706–707 (1995).
Cetinel, B. et al. Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report. Neurourol. Urodyn. 32, 1047–1057 (2013).
Panicker, J. N., Fowler, C. J. & Kessler, T. M. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 14, 720–732 (2015).
The National Institute for Health and Care Excellence. Urinary incontinence in neurological disease: assessment and management. [online], (2012).
Abrams, P. et al. 4th International Consultation on Incontinence. Recommendations of the international scientific committee. Evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol. Urodyn. 29, 213–240 (2010).
Mingat, N. et al. Prospective study of methods of renal function evaluation in patients with neurogenic bladder dysfunction. Urology 82, 1032–1037 (2013).
Caramella, D. et al. Videourodynamics in patients with neurogenic bladder due to multiple sclerosis: our experience. Radiol. Med. 116, 432–443 (2011).
Bryant, C. M., Dowell, C. J. & Fairbrother, G. Caffeine reduction education to improve urinary symptoms. Br. J. Nurs. 11, 560–565 (2002).
Klarskov, P., Heely, E., Nyholdt, I., Rottensten, K. & Nordenbo, A. Biofeedback treatment of bladder dysfunction in multiple sclerosis. A randomized trial. Scand. J. Urol. Nephrol. Suppl. 157, 61–65 (1994).
Vahtera, T., Haaranen, M., Viramo-Koskela, A. L. & Ruutiainen, J. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin. Rehabil. 11, 211–219 (1997).
McClurg, D., Ashe, R. G. & Lowe-Strong, A. S. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis — a double blind, placebo controlled, randomised clinical trial. Neurourol. Urodyn. 27, 231–237 (2008).
McClurg, D., Ashe, R. G., Marshall, K. & Lowe-Strong, A. S. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol. Urodyn. 25, 337–348 (2006).
Lucio, A., D'Ancona, C., Lopes, M., Perissinotto, M. & Damasceno, B. The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis. Mult. Scler. 20, 1761–1768 (2014).
Deffieux, X. et al. Pelvic floor rehabilitation for female urinary incontinence: mechanisms of action [French]. Prog. Urol. 23, 491–501 (2013).
De Ridder, D., Vermeulen, C., Ketelaer, P., Van Poppel, H. & Baert, L. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol. Belg. 99, 61–64 (1999).
de Sèze, M. & Gamé, X. Multiple sclerosis and pelviperineology: urinary and sexual dysfunctions and pregnancy [French]. Prog. Urol. 24, 483–494 (2014).
De Ridder, D. et al. Conservative bladder management in advanced multiple sclerosis. Mult. Scler. 11, 694–699 (2005).
Madhuvrata, P., Singh, M., Hasafa, Z. & Abdel-Fattah, M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur. Urol. 62, 816–830 (2012).
Fader, M. et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J. Urol. 177, 208–213 (2007).
van Rey, F. & Heesakkers, J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv. Urol. 2011, 834753 (2011).
Nicholas, R. S., Friede, T., Hollis, S. & Young, C. A. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst. Rev. 1, CD004193 (2009).
Gajewski, J. B. & Awad, S. A. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J. Urol. 135, 966–968 (1986).
Hebjorn, S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil). Urol. Int. 32, 209–217 (1977).
Ethans, K. D., Nance, P. W., Bard, R. J., Casey, A. R. & Schryvers, O. I. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J. Spinal Cord Med. 27, 214–218 (2004).
Amend, B. et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur. Urol. 53, 1021–1028 (2008).
Valiquette, G., Herbert, J. & Maede-D'Alisera, P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch. Neurol. 53, 1270–1275 (1996).
Eckford, S. B., Kohler-Ockmore, J. & Feneley, R. C. Long-term follow-up of transvaginal urethral closure and suprapubic cystostomy for urinary incontinence in women with multiple sclerosis. Br. J. Urol. 74, 319–321 (1994).
Kim, J.-H. in Primer on Multiple Sclerosis (ed. Giesser, B. S.) Ch. 15, 197–206 (Oxford Univ. Press, 2011).
Zahariou, A., Karamouti, M., Karagiannis, G. & Papaioannou, P. Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int. Urol. Nephrol. 40, 65–69 (2008).
Tubridy, N., Addison, R. & Schon, F. Long term use of desmopressin for urinary symptoms in multiple sclerosis. Mult. Scler. 5, 416–417 (1999).
Hoverd, P. A. & Fowler, C. J. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 65, 778–780 (1998).
Fredrikson, S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol. Scand. 94, 31–34 (1996).
Hilton, P., Hertogs, K. & Stanton, S. L. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 46, 854–855 (1983).
Bosma, R., Wynia, K., Havlíková, E., De Keyser, J. & Middel, B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol. Scand. 112, 1–5 (2005).
Hedlund, P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol. Urodyn. 33, 46–53 (2014).
Freeman, R. M. et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic Floor Dysfunct. 17, 636–641 (2006).
Brady, C. M. et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10, 425–433 (2004).
Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G. & Fowler, C. J. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 16, 1349–1359 (2010).
Schurch, B. et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 174, 196–200 (2005).
Cruz, F. et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 60, 742–750 (2011).
Ginsberg, D. et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J. Urol. 187, 2131–2139 (2012).
Ehren, I. et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity. Scand. J. Urol. Nephrol. 41, 335–340 (2007).
Mangera, A. et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 60, 784–795 (2011).
Apostolidis, A., Dasgupta, P. & Fowler, C. J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 49, 644–650 (2006).
Kalsi, V. et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann. Neurol. 62, 452–457 (2007).
Mehnert, U., Birzele, J., Reuter, K. & Schurch, B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J. Urol. 184, 1011–1016 (2010).
Karsenty, G. et al. A novel technique to achieve cutaneous continent urinary diversion in spinal cord-injured patients unable to catheterize through native urethra. Spinal Cord 46, 305–310 (2007).
Gamé, X. et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur. Urol. 53, 613–618 (2008).
Lekka, E. & Lee, L. K. Successful treatment with intradetrusor botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur. Urol. 50, 806–810 (2006).
Stoller, M. Afferent nerve stimulation for pelvic floor dysfunction. Eur. Urol. 35 (Suppl. 2), 16 (1999).
Kabay, S. C., Kabay, S., Yucel, M. & Ozden, H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol. Urodyn. 28, 62–67 (2009).
Kabay, S. C., Yucel, M. & Kabay, S. Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. Urology 71, 641–645 (2008).
Gobbi, C. et al. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult. Scler. 17, 1514–1519 (2011).
Andrews, B. J. & Reynard, J. M. Transcutaneous posterior tibial nerve stimulation for treatment of detrusor hyperreflexia in spinal cord injury. J. Urol. 170, 926 (2003).
Govier, F. E., Litwiller, S., Nitti, V., Kreder, K. J. Jr & Rosenblatt, P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J. Urol. 165, 1193–1198 (2001).
van Balken, M. R., Vergunst, H. & Bemelmans, B. L. H. Prognostic factors for successful percutaneous tibial nerve stimulation. Eur. Urol. 49, 360–365 (2006).
Kabay, S. et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol. Urodyn. 28, 964–968 (2009).
de Seze, M. et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol. Urodyn. 30, 306–311 (2011).
Chartier-Kastler, E. J. et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J. Urol. 164, 1476–1480 (2000).
Craggs, M. & McFarlane, J. Neuromodulation of the lower urinary tract. Exp. Physiol. 84, 149–160 (1999).
Kessler, T. M. et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur. Urol. 58, 865–874 (2010).
Wallace, P. A., Lane, F. L. & Noblett, K. L. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am. J. Obstet. Gynecol. 197, 96.e1–96.e5 (2007).
Chaabane, W. et al. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol. Urodyn. 30, 547–550 (2011).
Minardi, D. & Muzzonigro, G. Sacral neuromodulation in patients with multiple sclerosis. World J. Urol. 30, 123–128 (2011).
Peters, K. M., Kandagatla, P., Killinger, K. A., Wolfert, C. & Boura, J. A. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology 81, 738–743 (2013).
Minardi, D. & Muzzonigro, G. Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report. Neuromodulation 8, 176–181 (2005).
Marinkovic, S. P. & Gillen, L. M. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int. Urogynecol J. 21, 223–228 (2010).
Andretta, E., Simeone, C., Ostardo, E., Pastorello, M. & Zuliani, C. Usefulness of sacral nerve modulation in a series of multiple sclerosis patients with bladder dysfunction. J. Neurol. Sci. 347, 257–261 (2014).
Zachoval, R. et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol. Int. 70, 21–26 (2003).
Venn, S. N. & Mundy, A. R. Long-term results of augmentation cystoplasty. Eur. Urol. 34, 40–42 (1998).
Herschorn, S. Long-term outcome of augmentation enterocystoplasty for neurogenic bladder. J. Urol. 187, e668 (2012).
Gould, J. J. & Stoffel, J. T. Robotic enterocystoplasty: technique and early outcomes. J. Endourol. 25, 91–95 (2011).
Liard, A., Séguier-Lipszyc, E., Mathiot, A. & Mitrofanoff, P. The Mitrofanoff procedure: 20 years later. J. Urol. 165, 2394–2398 (2001).
Moreno, J. G. et al. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch. Phys. Med. Rehabil. 76, 758–762 (1995).
Stein, R. et al. Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment? J. Urol. 163, 568–573 (2000).
Vian, E., Soustelle, L., Viale, S. & Costa, P. A technique of continent vesicostomy with ileocystoplasty: study of 32 patients. Prog. Urol. 19, 116–121 (2009).
Jacques, C., David, G. & Gilles, K. (eds) Textbook of the Neurogenic Bladder 3rd edn (CRC Press, 2011).
Legrand, G. et al. Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology 78, 937–941 (2011).
Guillotreau, J. et al. Prospective evaluation of laparoscopic assisted cystectomy and ileal conduit in advanced multiple sclerosis. Urology 80, 852–857 (2012).
Lapides, J., Diokno, A. C., Silber, S. J. & Lowe, B. S. Clean, intermittent self-catheterization in the treatment of urinary tract disease. Trans. Am. Assoc. Genitourin. Surg. 63, 92–96 (1971).
Kirchhof, K. & Fowler, C. J. The value of the Kurtzke Functional Systems Scales in predicting incomplete bladder emptying. Spinal Cord 38, 409–413 (2000).
Vahter, L. et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult. Scler. 15, 379–384 (2009).
Seth, J. H., Haslam, C. & Panicker, J. N. Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer. Adherence 8, 191–198 (2014).
Sand, P. K. & Sand, R. I. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis. Mon. 59, 261–268 (2013).
Yonnet, G. J., Fjeldstad, A. S., Carlson, N. G. & Rose, J. W. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int. J. MS Care 15, 66–72 (2013).
Schulte-Baukloh, H. et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol. Urodyn. 25, 110–115 (2006).
Castel-Lacanal, E. et al. Impact of intermittent catheterization on the quality of life of multiple sclerosis patients. World J. Urol. 31, 1445–1450 (2013).
O'Riordan, J. I. et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J. Urol. 153, 1114–1116 (1995).
Weld, K. J. & Dmochowski, R. R. Effect of bladder management on urological complications in spinal cord injured patients. J. Urol. 163, 768–772 (2000).
Bennett, C. J., Young, M. N., Adkins, R. H. & Diaz, F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J. Urol. 153, 1458–1460 (1995).
Larsen, L. D., Chamberlin, D. A., Khonsari, F. & Ahlering, T. E. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology 50, 418–422 (1997).
Mitsui, T., Minami, K., Furuno, T., Morita, H. & Koyanagi, T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur. Urol. 38, 434–438 (2000).
West, D. A. et al. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 53, 292–297 (1999).
James, R., Frasure, H. E. & Mahajan, S. T. Urinary catheterization may not adversely impact quality of life in multiple sclerosis patients. ISRN Neurol. 2014, 167030 (2014).
Chancellor, M. B. et al. Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. J. Urol. 161, 1893–1898 (1999).
Fontaine, E. et al. Reappraisal of endoscopic sphincterotomy for post-traumatic neurogenic bladder: a prospective study. J. Urol. 155, 277–280 (1996).
Gallien, P. et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry 76, 1670–1676 (2005).
de Sèze, M. et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 42, 56–62 (2002).
Phelan, M. W. et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 165, 1107–1110 (2001).
Utomo, E., Groen, J. & Blok, B. F. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst. Rev. 5, CD004927 (2014).
Acknowledgements
V.P. acknowledges support from the European Urological Scholarship Programme
Author information
Authors and Affiliations
Contributions
All authors researched data for this article, and made a significant contribution to discussions of content. V.P. wrote the manuscript, and all authors reviewed and/or edited the manuscript prior to submission.
Corresponding author
Ethics declarations
Competing interests
E.C.K. has acted as a consultant of Allergan, Astellas, Axonics, Coloplast, Medtronic and and, and has received honoraria from Allergan, Astellas, Coloplast, Medtronic and Pfizer. V.P. and J.P. declare no competing interests.
Rights and permissions
About this article
Cite this article
Phé, V., Chartier–Kastler, E. & Panicker, J. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13, 275–288 (2016). https://doi.org/10.1038/nrurol.2016.53
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.53
- Springer Nature Limited
This article is cited by
-
Overactive bladder and multiple sclerosis in the University Hospital of Oujda
African Journal of Urology (2023)
-
Unmet needs in the management of neurourological disorders within the last 50 years
World Journal of Urology (2023)
-
A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis
Journal of Neurology (2023)
-
UTI assessment tool for intermittent catheter users: a way to include user perspectives and enhance quality of UTI management
BMC Nursing (2022)